Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study Comparing the Safety & Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, & Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis
Brief Summary: To compare the efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with that of methotrexate monotherapy in the treatment of rheumatoid arthritis over 88 weeks.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MLTA3698A, Drug: leflunomide, Drug: methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab, Drug: leflunomide, Drug: methotrexate, Drug: placebo | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: leflunomide, Drug: methotrexate, Drug: placebo | Intervention Type: DRUG; Name: MLTA3698A; Assigned to Arm(s): A | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): B | Intervention Type: DRUG; Name: leflunomide; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B, C
C: Arm Label: 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 | Arm Label: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biologic TNFi | Intervention Type: DRUG; Name: CP 690,550; Assigned to Arm(s): 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2 | Intervention Type: BIOLOGICAL; Name: Biologic TNFi; Assigned to Arm(s): adalimumab
D: Arm Label: CDP870 100mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 100mg | Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 200mg | Arm Label: CDP870 400mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 400mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870 400mg; Assigned to Arm(s): CDP870 400mg | Intervention Type: DRUG; Name: CDP870 200mg; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: CDP870 100mg; Assigned to Arm(s): CDP870 100mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo

Answer: A